Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later May 2026 → May 26, 2027
See other at-risk trials from Sichuan Huiyu Pharmaceutical Co., Ltd

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from May 2026 to May 26, 2027
    • Study completion pushed from Oct 2026 to Oct 26, 2027
    • Eligibility criteria expanded, about 29 words
    • Secondary endpoints: details revised at 3 of 13 entries
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 8, 2024 to Oct 24, 2024
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.
Trial Details
NCT Number NCT06639256
Lead Sponsor Sichuan Huiyu Pharmaceutical Co., Ltd
Conditions
(from sponsor)		 Safety, Tolerability, Efficacy
Enrollment 258 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov